TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
This is a single center, single arm phase I trial to test the feasibility and safety of
Tumor- Infiltrating Lymphocyte-Adoptive Cell Therapy (TIL-ACT) followed by nivolumab rescue
in advanced metastatic melanoma patients. The trial is based on lymphodepleting chemotherapy
followed by ACT, utilizing ex vivo expanded TILs in combination with high dose interleukin-2
(IL-2) (optional, depending on patient's tolerance), followed by nivolumab rescue (if
indicated) for a maximum duration of 2 years.